Pathfinder Cell Therapy, Inc.
PFND
$0.00
$0.000.00%
OTC PK
| 09/30/2015 | 06/30/2015 | 03/31/2015 | 12/31/2014 | 09/30/2014 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -26.20% | -42.00% | -37.38% | -38.66% | -14.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.88% | -45.66% | -51.77% | -46.57% | -35.06% |
| Operating Income | 1.88% | 45.66% | 51.77% | 46.57% | 33.44% |
| Income Before Tax | -1.76% | 33.13% | 43.09% | 36.58% | 23.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.76% | 33.13% | 43.09% | 36.58% | 23.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.76% | 33.13% | 43.09% | 36.58% | 23.66% |
| EBIT | 1.88% | 45.66% | 51.77% | 46.57% | 33.44% |
| EBITDA | 1.89% | 45.83% | 51.90% | 46.44% | 33.54% |
| EPS Basic | 0.00% | 40.00% | 42.86% | 42.86% | 33.33% |
| Normalized Basic EPS | 0.00% | 33.33% | 40.00% | 25.00% | 0.00% |
| EPS Diluted | 0.00% | 40.00% | 42.86% | 42.86% | 33.33% |
| Normalized Diluted EPS | 0.00% | 33.33% | 40.00% | 25.00% | 0.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |